Terms: = Bone cancer AND MYOD1, ENSG00000129152, 4654, P15172, PUM, MYOD, MYF3 AND Clinical Outcome
3 results:
1. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract] [Full Text] [Related]
2. Cytogenetic and real-time quantitative reverse-transcriptase polymerase chain reaction analyses in pleomorphic rhabdomyosarcoma.
Li G; Ogose A; Kawashima H; Umezu H; Hotta T; Tohyama T; Ariizumi T; Endo N
Cancer Genet Cytogenet; 2009 Jul; 192(1):1-9. PubMed ID: 19480930
[TBL] [Abstract] [Full Text] [Related]
3. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
Krsková L; Mrhalová M; Sumerauer D; Kodet R
Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
[TBL] [Abstract] [Full Text] [Related]
